The levels of CD206, a marker of immunosuppressive M2-polarized macrophages, and CD11b+ myeloid-derived suppressor cells (MDSCs), which contribute to tumor progression, were significantly reduced in the combination treatment group (Fig. 2B, bottom row). This evidence concerns the gene ITGAM and neoplasm.